Minoxidil may inhibit androgenreceptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgenreceptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgenreceptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
A method for treating androgenic alopecia using minoxidil, antiandrogens, exercise, and cold exposure to promote hair growth. Environmental factors and lifestyle changes, like diet and exercise, can improve treatment effectiveness.
Treating androgenic alopecia with minoxidil, finasteride, and antiandrogens, alongside exercise, cryotherapy, and natural substances to stimulate cold receptors for better hair growth. The method focuses on enhancing treatment effectiveness by considering environmental and behavioral factors and the role of cold receptors and muscle stress.